help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grouzmann, E.
Right arrow Articles by Bohuon, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grouzmann, E.
Right arrow Articles by Bohuon, C.

Journal of Clinical Endocrinology & Metabolism, Vol 68, 808-813, Copyright © 1989 by Endocrine Society

ARTICLES

Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors

E Grouzmann, E Comoy and C Bohuon
Laboratoire d'Immunotoxicologie-UER de Pharmacie, Chatenay-Malabry, France.

In order to develop an immunoradiometric assay for human neuropeptide (hNPY), a recently discovered and potent vasoconstrictor 36-amino-acid peptide, we used hNPY and some of its subpeptides to prepare monoclonal anti-NPY antibodies. Two monoclonal antibodies with high affinity for hNPY, that is affinity constants in the range of 10(10) mol/L-1, which respectively, reacted with the 9-18 portion and the 32-36 portion of hNPY were used in the immunoradiometric system. The assay was highly specific, NPY-related peptides such as pancreatic polypeptide and peptide YY not being detected. The lower limit of sensitivity was 0.5 pmol/L. In 303 normal subjects, plasma NPY concentrations were less than 0.5 pmol/L in 67%, 0.5 to 5.0 pmol/L in 25% and 5.1 to 30 pmol/L in the remaining 8%. A value of 7.5 pmol/L (95th percentile value in the normal group) was considered as the upper limit of normal. Among 111 patients with various neuroendocrine tumors, elevated plasma NPY concentrations were found in patients with pheochromocytomas and neuroblastomas, the highest plasma levels being found in patients with malignant pheochromocytomas. We conclude that patients with neuroendocrine tumors, especially secreting and or malignant tumors of the sympathochromaffin system, often have elevated plasma NPY concentrations.


This article has been cited by other articles:


Home page
 J EndocrinolHome page
S. Cleary, J. K Phillips, T.-T. Huynh, K. Pacak, A. G Elkahloun, J. Barb, R. A Worrell, D. S Goldstein, and G. Eisenhofer
Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome
J. Endocrinol., May 1, 2007; 193(2): 225 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Kitlinska, K. Abe, L. Kuo, J. Pons, M. Yu, L. Li, J. Tilan, L. Everhart, E. W. Lee, Z. Zukowska, et al.
Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest-Derived Tumors
Cancer Res., March 1, 2005; 65(5): 1719 - 1728.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society